OptiTROP-Lung04: what clinicians are saying
sacituzumab tirumotecan (SKB264) in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC · NCT05870319 ↗ · Phase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
The clinicians cited read OptiTROP-Lung04 as supporting an active option that could move platinum later in treatment, but differ on readiness to use sac-TMT. One medical oncologist supports treatment change where it is available; another anticipates future rather than immediate change. A speaker would move toward sac-TMT only with access and global replication. Clinicians still seek CNS data, while final survival estimates are described through commentary rather than a separate final-results publication.
Created with AI · how we check it
- edition 1
- commentary checked Nov 20, 2026
- 125 verified statements
This edition $750, with MCP access for your AI agent. Get this report
11 findings, and what sits behind each
01. Uptake: what speakers say
6 of the report's 16 cited clinicians · 16 statements from 9 speakers in 11 sources, 4 of them podcasts or videos · 15 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Progression-free survival (PFS), Safety and tolerability, Population and setting, Secondary endpoints, The comparison.
02. China-only evidence: where speakers split on requiring global confirmation
5 of the report's 16 cited clinicians · 13 statements from 8 speakers in 10 sources, 2 of them podcasts or videos · 10 passages
Limitations recorded: 4.
Draws on: Design and conduct, The comparison.
03. Grade ≥3: what speakers say
5 of the report's 16 cited clinicians · 19 statements from 10 speakers in 14 sources, 4 of them podcasts or videos · 17 passages
Limitations recorded: 5.
Draws on: Safety and tolerability, Primary endpoint: Progression-free survival (PFS), Secondary endpoints, Population and setting, The comparison, Design and conduct.
04. CNS activity: why most clinicians seek more evidence on brain metastases
5 of the report's 16 cited clinicians · 7 statements from 5 speakers in 6 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Progression-free survival (PFS), Secondary endpoints, The comparison.
05. OS benefit: most speakers highlight its size; a clinician notes a nominal p value
9 of the report's 16 cited clinicians · 25 statements from 14 speakers in 18 sources, 2 of them podcasts or videos · 23 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, Primary endpoint: Progression-free survival (PFS), Design and conduct, Population and setting, The comparison, Safety and tolerability.
06. Post-EGFR-TKI: most speakers weigh options but a clinician cannot yet rank them
4 of the report's 16 cited clinicians · 20 statements from 7 speakers in 12 sources, 4 of them podcasts or videos · 14 passages
Limitations recorded: 5.
Draws on: The comparison, Population and setting, Safety and tolerability.
07. Post-EGFR-TKI choices: why speakers want testing and biomarkers to guide therapy
2 of the report's 16 cited clinicians · 11 statements from 3 speakers in 4 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 4.
Draws on: Population and setting, The comparison, Design and conduct.
08. TROP2 ADCs: where speakers split on class-wide versus drug-specific implications
3 of the report's 16 cited clinicians · 9 statements from 7 speakers in 7 sources, 3 of them podcasts or videos · 8 passages
Limitations recorded: 3.
Draws on: Population and setting, The comparison.
Beyond the trial population
09. ADC R&D: what speakers say
3 of the report's 16 cited clinicians · 8 statements from 6 speakers in 7 sources, 3 of them podcasts or videos · 9 passages
Limitations recorded: 4.
10. Prior ADC work: most speakers note activity signals; most see care changing
1 of the report's 16 cited clinicians · 9 statements from 3 speakers in 6 sources, 2 of them podcasts or videos · 6 passages
Limitations recorded: 4.
11. From EGFR-mutant to PD-L1-negative NSCLC: how a speaker sees an ADC shift
No named clinician · accounts and unnamed speakers · 1 statement from 1 speaker in 1 source · 1 passage
Limitations recorded: 1.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 11
6 of the report's 16 cited clinicians
Uptake: what speakers say
16 statements from 9 speakers in 11 sources, 4 of them podcasts or videos
- 16
- statements
- 15
- passages
- 11
- sources
- 9
- speakers
What the statements areViews 16Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 16Giving context 1Recorded with the findingLimitations: 3
7 posts and articles · 4 podcasts and video
Draws on: Primary endpoint: Progression-free survival (PFS), Safety and tolerability, Population and setting, Secondary endpoints, The comparison.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
3 of the 11 findings and 12 of the 125 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (10)
ADC, antibody–drug conjugate; CNS, central nervous system; EGFR, epidermal growth factor receptor; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival.
The full OptiTROP-Lung04 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
Where sacituzumab tirumotecan is available outside China, is global confirmation of OptiTROP-Lung04 needed before using it to defer platinum chemotherapy after EGFR-TKI progression in advanced EGFR-mutant NSCLC?
From findings F1 (16 statements from 9 speakers in 11 sources) and F2 (13 statements from 8 speakers in 10 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 71commentary sources screened
- 38sources cited by verified statements
- 28named in screened sources
- 28speakers cited in the report
- 24cited speakers with a verified identity
16 cited clinicians, speakers with a confirmed clinical role, of them 16 physicians. By role and specialty:
- 15 physician, Medical oncology
- 1 physician, specialty not confirmed
Also in the sources: 2 organizational or shared accounts, not counted as people.
- 125verified statements, each linked to its source
- 52of them from speakers with a confirmed clinical role
- 11findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 125 | Paid |
| Who said each statement: the cited speakers | 28 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 16 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 24 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 38 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
14 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression-free survival (PFS) | 15 | 14 |
| Secondary endpoints | 19 | 16 |
| Population and setting | 15 | 7 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 20 | 12 |
| Safety and tolerability | 18 | 13 |
| Design and conduct | 16 | 9 |
| Practice-change thresholds and platinum deferral | 17 | 13 |
| Geographic applicability, regulatory translation and access | 14 | 11 |
| Intracranial activity and patient-relevant outcomes | 7 | 6 |
| Resistance work-up and treatment sequencing | 13 | 6 |
| Biological rationale and ADC differentiation | 9 | 7 |
| Earlier-study context and uncertain study descriptions | 11 | 8 |
| Future combinations and earlier-line development | 9 | 8 |
| Analysis maturity, subsequent therapy and statistical interpretation | 17 | 11 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
125 verified statements from 38 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 48 statements · 39% | ||||
| YouTube | 38 | 6 | 8 | |
| Podcasts | 10 | 1 | 1 | |
| Posts · 73 statements · 58% | ||||
| X threads | 34 | 15 | 33 | |
| LinkedIn posts | 34 | 11 | 11 | |
| Bluesky threads | 5 | 3 | 18 | |
| Primary sources · 4 statements · 3%cited for context, not screened | ||||
| Publications | 3 | 1 | — | |
| Registry | 1 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 39 / quarter
- Screened window
- Jul 25, 2023 → Nov 13, 2026
- Cited window
- Jun 1, 2025 → Nov 13, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy
- Also known as
- OptiTROP-4
- Registry
- NCT05870319
- Study IDs
- SKB264-Ⅲ-09
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 376 actual
- Registered
- 2023-05-23
- Start
- 2023-06-26 actual
- Primary completion
- 2024-07-11 actual
- Primary endpoint
- Progression-free survival (PFS)
- Interventions
- 4 registered
More on: Non-small cell lung cancer
Discussed at: ESMO Congress 2026
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- Not yet captured in this edition: a view on alternative antibody–drug conjugates’ benefit–risk, evidence maturity and geographic applicability after EGFR-TKI failure; a view on alternative ADC efficacy, toxicity, dose modification and supportive-care needs after EGFR-TKI failure.
- 57 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 64 sources about other trials or topics are not included.
Show all 14 known gaps +Fewer −
- The sources reviewed for this edition are not a representative sample of HCPs. Repeated posts and presentation summaries do not establish independent agreement.
- Public discussion that did not use recognizable trial names or wording may be absent. One potentially relevant X discussion could not be read.
- Several recorded passages cannot be attributed to a named speaker. They remain attached to their discussion or episode and cannot establish additional independent participants.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The linked publication reports final PFS and preplanned interim OS. Final OS estimates in this report come from commentary about the 2026 update, not a separate final-results publication.
- Some sources differ on the comparator, treatment history, endpoint hierarchy, safety measure or study name. Their descriptions remain attributed commentary rather than a single reconciled result.
- No full protocol was available in the sources reviewed, and the regulatory material does not establish an exact label for SKB264. The report therefore does not determine regulatory status or resolve protocol-level questions.
- Earlier or unidentified sac-TMT studies provide contextual material, not evidence for Lung04's own platinum-comparator result.
- Descriptions of alternative-regimen and access discussions are incomplete. SAFFRON is represented here by biomarker-selection comments rather than a full quantitative benefit–risk assessment, and not every speaker's assessment of the other ADCs is available. The report therefore cannot provide an exhaustive account of reasons to choose or withhold each alternative.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 20, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. OptiTROP-Lung04 (NCT05870319): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/optitrop-lung04-nct05870319
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "OptiTROP-Lung04" (NCT05870319), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "optitrop-lung04-nct05870319". If you cannot make requests, read https://www.erudio.com/reports/optitrop-lung04-nct05870319.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05870319", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05870319 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/optitrop-lung04-nct05870319.json
curl https://www.erudio.com/reports/optitrop-lung04-nct05870319.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "optitrop-lung04-nct05870319" })release 9d960d780150a19405aa25d85f2ca1c6ebb6322b4aaea7c51101c751699811a5
Questions
How much does the OptiTROP-Lung04 report cost?
One edition costs $750 (Focused · 125 verified statements · 52 from 16 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the OptiTROP-Lung04 report cover?
125 statements from 38 sources (1 podcast, 6 videos, 29 posts, 1 paper, 1 registry record), 52 of them from 16 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the OptiTROP-Lung04 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "optitrop-lung04-nct05870319" }) previews it and create_order({ "report": "optitrop-lung04-nct05870319", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the OptiTROP-Lung04 report?
Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.